Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290099 | 1.00 | DPP4 (0.56) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL4952155 | 0.90 | DPP4 (0.69) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL14282783 | 0.90 | DPP4 (0.69) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8289046 | 0.90 | DPP4 (0.55) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL4957414 | 0.85 | DPP4 (0.77) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8289006 | 0.85 | DPP4 (0.77) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL7852591 | 0.81 | DPP4 (0.49) | DPP4DPP8DPP9DPP7KLK5 | |
| SCHEMBL8373795 | 0.81 | DPP4 (0.49) | DPP4DPP8DPP9DPP7KLK5 | |
| SCHEMBL8290132 | 0.81 | DPP4 (0.51) | DPP4DPP8DPP9DPP7KLK5 | |
| SCHEMBL14421707 | 0.81 | DPP4 (0.50) | DPP4DPP8DPP9DPP7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.